Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | METAP2 | P50579 | 1/20 | 0.41 |
| ▸ | METAP1 | P53582 | 1/20 | 0.41 |
| ▸ | HTR1B | P28222 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15171136 | 1.00 | ALDH1A1 (0.47) | ALDH1A1CYP2C9CYP2C19CYP1A2TSHR | |
| SCHEMBL1527192 | 0.86 | ALDH1A1 (0.52) | ALDH1A1CYP2C9CYP2C19CYP1A2TSHR | |
| SCHEMBL28707980 | 0.86 | ALDH1A1 (0.52) | ALDH1A1CYP2C9CYP2C19CYP1A2TSHR | |
| SCHEMBL29435914 | 0.86 | ALDH1A1 (0.52) | ALDH1A1CYP2C9CYP2C19CYP1A2TSHR | |
| SCHEMBL3923359 | 0.81 | CYP1A2 (0.47) | ALDH1A1CYP2C9CYP2C19CYP1A2TSHR | |
| SCHEMBL3923362 | 0.81 | CYP1A2 (0.47) | ALDH1A1CYP2C9CYP2C19CYP1A2TSHR | |
| SCHEMBL8375544 | 0.81 | CYP2C9 (0.47) | ALDH1A1CYP2C9CYP2C19CYP1A2TSHR | |
| SCHEMBL2734713 | 0.81 | ALDH1A1 (0.47) | ALDH1A1CYP2C9CYP2C19CYP1A2TSHR | |
| SCHEMBL4949690 | 0.81 | CYP2C9 (0.47) | ALDH1A1CYP2C9CYP2C19CYP1A2TSHR | |
| SCHEMBL6313224 | 0.80 | TSHR (0.46) | ALDH1A1CYP2C9CYP2C19CYP1A2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7132392-B1 | Inhibition of cell motility and angiogenesis by inhibitors of Grb2-SH2-domain | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-11-07 | — | — | US | claimed |
| US-RE39593-E1 | 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects | GRUENENTHAL GMBH (DE) | 2007-04-24 | — | — | US | disclosed |
| US-6344558-B1 | ANALGESICS | GRUENTHAL GMBH (DE) | 2002-02-05 | — | — | US | disclosed |
| US-20020010178-A1 | 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effect | GRUENENTHAL GMBH | 2002-01-24 | — | — | US | disclosed |
| US-6248737-B1 | ANALGESICS | GRUENENTHAL GMBH (DE) | 2001-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010178-A1 | 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effect | OPRM1, OPRK1, OPRD1 | ALDH1A1 135/4885CYP2C9 341/4885CYP2C19 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.